According to the results of a new study published in the journal Molecular Biology Reports, combining cannabidiol (CBD) with Vitamin D may significantly enhance anti-cancer activity against hepatocellular carcinoma (HCC), one of the deadliest forms of liver cancer worldwide.
The study was conducted by researchers from Yeditepe University, who examined how the two compounds interact in human liver cancer cells.
Using two established HCC cell lines, Hep3B and Huh7, researchers evaluated the effects of CBD and Vitamin D both individually and in combination. Cell viability was measured through MTS assays, while drug interactions were analyzed using the Chou–Talalay method to determine whether the compounds worked synergistically.
The results show that the combined treatment led to a synergistic reduction in cancer cell viability in both cell lines, meaning the two compounds were more effective together than when used separately. The combination also produced lower IC₅₀ values compared to either treatment alone, indicating greater potency at reduced concentrations.
Further analysis revealed that the dual treatment enhanced apoptotic signaling and reduced cell proliferation, although the exact molecular effects differed between the two cell lines. In Hep3B cells, the combination triggered G1 phase cell cycle arrest, altered autophagy-related gene expression, and impacted DNA damage response pathways. Huh7 cells demonstrated distinct transcriptional changes, suggesting that cellular context influences how the therapy works.
While the findings are limited to in vitro experiments, the study provides mechanistic insight into how CBD and Vitamin D may work together to suppress liver cancer cell growth. The authors conclude that the combination warrants further investigation as a potential therapeutic strategy for hepatocellular carcinoma.
Sponsored
